IN2014DN08088A - - Google Patents
Info
- Publication number
- IN2014DN08088A IN2014DN08088A IN8088DEN2014A IN2014DN08088A IN 2014DN08088 A IN2014DN08088 A IN 2014DN08088A IN 8088DEN2014 A IN8088DEN2014 A IN 8088DEN2014A IN 2014DN08088 A IN2014DN08088 A IN 2014DN08088A
- Authority
- IN
- India
- Prior art keywords
- oil
- prophylaxis
- treatment
- water emulsion
- neurological damage
- Prior art date
Links
- 230000006378 damage Effects 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 230000000926 neurological effect Effects 0.000 abstract 2
- 239000007764 o/w emulsion Substances 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000009514 concussion Effects 0.000 abstract 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical group C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 230000008736 traumatic injury Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to hormone containing oil in water emulsion for parenteral administration comprising progestogen and/or estrogen; a phospholipid comprising one or two omega 3 fatty acid moieties; and an oil as well as a pharmaceutical composition comprising or consisting of said oil in water emulsion. The pharmaceutical is especially for use in the treatment or prophylaxis of neurological damage after strokes and/or trauma and/or for use in the treatment or prophylaxis of neurological damage after concussion and/or traumatic injury to the central nervous system.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12157546 | 2012-02-29 | ||
| PCT/EP2013/053679 WO2013127727A1 (en) | 2012-02-29 | 2013-02-25 | Hormone containing emulsion comprising krill phospholipids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08088A true IN2014DN08088A (en) | 2015-05-01 |
Family
ID=47748635
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8089DEN2014 IN2014DN08089A (en) | 2012-02-29 | 2013-02-25 | |
| IN8088DEN2014 IN2014DN08088A (en) | 2012-02-29 | 2013-02-25 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8089DEN2014 IN2014DN08089A (en) | 2012-02-29 | 2013-02-25 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150018320A1 (en) |
| EP (2) | EP2819650A1 (en) |
| JP (2) | JP2015508791A (en) |
| KR (2) | KR102027613B1 (en) |
| CN (3) | CN104136008A (en) |
| BR (2) | BR112014021390A2 (en) |
| CA (2) | CA2865030C (en) |
| ES (1) | ES2659466T3 (en) |
| IL (2) | IL233760A0 (en) |
| IN (2) | IN2014DN08089A (en) |
| MX (2) | MX2014010445A (en) |
| NO (1) | NO2819649T3 (en) |
| PL (1) | PL2819649T3 (en) |
| PT (1) | PT2819649T (en) |
| RU (2) | RU2014139008A (en) |
| WO (2) | WO2013127727A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| WO2014057522A1 (en) | 2012-10-12 | 2014-04-17 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10441560B2 (en) | 2013-03-15 | 2019-10-15 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| AU2014230444B2 (en) | 2013-03-15 | 2018-05-17 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| KR101588247B1 (en) | 2013-04-17 | 2016-01-25 | 경희대학교 산학협력단 | Composition for preventing or treating stroke or degenerative brain disease |
| US20160213639A1 (en) * | 2013-10-07 | 2016-07-28 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| GB201402457D0 (en) | 2014-02-12 | 2014-03-26 | Aker Biomarine As | Capsules containing high doses of phospholipids |
| GB201402450D0 (en) | 2014-02-12 | 2014-03-26 | Aker Biomarine As | Liquid phospholipid-containing compositions for preperation of pharmaceuticals |
| GB201407345D0 (en) | 2014-04-25 | 2014-06-11 | Aker Biomarine As | Krill Phospholipid compositions |
| AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| MX2016013693A (en) | 2014-07-29 | 2017-10-31 | Therapeuticsmd Inc | Transdermal cream. |
| US11147841B2 (en) | 2014-12-19 | 2021-10-19 | Aker Biomarine Antarctic As | Enhanced omega-3 formulations |
| JP6814148B2 (en) * | 2015-03-31 | 2021-01-13 | フレゼニウス カービ ドイチュラント ゲーエムベーハー | Emulsion for parenteral administration |
| GB201509606D0 (en) * | 2015-06-03 | 2015-07-15 | Anabio Technologies Ltd | Microencapsulates containing stabilised marine-derived oil, and methods for production thereof |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| JP2019513709A (en) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | Steroid hormone pharmaceutical composition |
| CN105878184A (en) * | 2016-04-26 | 2016-08-24 | 天津市中升挑战生物科技有限公司 | Altrenogest nanometer emulsion and method for preparing same |
| PL3664628T3 (en) * | 2017-08-10 | 2025-04-07 | The Children's Medical Center Corporation | Methods and compositions relating to emulsions comprising fish oil and/or omega-3 fatty acids |
| CA3155749A1 (en) | 2019-12-20 | 2021-06-24 | Fresenius Kabi Austria Gmbh | Method for producing oil-in-water emulsions |
| DK4135684T3 (en) * | 2020-04-15 | 2025-09-15 | Univ Columbia | STABLE DIGLYCERIDE EMULSIONS AND METHODS FOR TREATING ORGAN DAMAGE |
| WO2022125484A1 (en) * | 2020-12-07 | 2022-06-16 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for neuroprotection in neonatal hypoxic-ischemic encephalopathy |
| GB202316026D0 (en) * | 2023-10-19 | 2023-12-06 | Theramex Hq Uk Ltd | Methods of prevention or treatment |
| WO2025083197A1 (en) * | 2023-10-20 | 2025-04-24 | Sativari UG (haftungsbeschränkt) | Liquid pharmaceutical formula for intravenous, subcutaneous or intramuscular application of one or more cannabinoids |
| DE102023128848A1 (en) * | 2023-10-20 | 2025-04-24 | Sativari UG (haftungsbeschränkt) | Liquid pharmaceutical formulation for intravenous, subcutaneous, or intramuscular administration of one or more cannabinoids |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2738253A1 (en) | 1977-08-25 | 1979-03-01 | Dabisch Tipp Ex Tech | BODY WITH REVERSIBLE TEMPERATURE-DEPENDENT TRANSPARENCY |
| DE2749265A1 (en) | 1977-11-03 | 1979-05-10 | Linde Ag | METHOD FOR BIOLOGICAL WASTE WATER TREATMENT |
| JPS60258110A (en) | 1984-06-05 | 1985-12-20 | Daigo Eiyou Kagaku Kk | Progesterone emulsified parenteral solution injectable intravenously |
| US5560364A (en) | 1995-05-12 | 1996-10-01 | The Board Of Regents Of The University Of Nebraska | Suspended ultra-sound induced microbubble cavitation imaging |
| US20100173876A1 (en) | 2000-12-19 | 2010-07-08 | The Board Of Regents Of The University Of Texas System | Oil-based nsaid compositions and methods for making and using same |
| US8729124B2 (en) | 2002-03-05 | 2014-05-20 | Pronova Biopharma Norge As | Use of EPA and DHA in secondary prevention |
| EP1488785A1 (en) | 2003-06-18 | 2004-12-22 | B. Braun Melsungen Ag | Oil emulsion for postnatal substitution of hormones |
| IL158552A0 (en) * | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Lipids containing omega-3 fatty acids |
| US8557861B2 (en) * | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
| US7473687B2 (en) | 2005-03-24 | 2009-01-06 | Emory University | Methods for the treatment of a traumatic central nervous system injury |
| PT1868614E (en) | 2005-03-24 | 2012-11-23 | Univ Emory | Dosage regimen for the treatment of a traumatic brain injury with progesterone |
| KR20130101596A (en) * | 2005-07-08 | 2013-09-13 | 마텍 바이오싸이언스스 코포레이션 | Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions |
| EP1973525B1 (en) | 2005-12-05 | 2014-04-30 | RBA Pharma Inc. | Emulsion-containing medical articles |
| AR059012A1 (en) * | 2006-01-13 | 2008-03-05 | Aker Biomarine Asa | EXTRACTS DERIVED FROM KRILL |
| JP5352961B2 (en) * | 2006-03-28 | 2013-11-27 | Ｊｎｃ株式会社 | Life-style related diseases prevention / treatment agents |
| CN101152186B (en) | 2007-09-05 | 2011-07-06 | 杭州平和安康医药科技有限公司 | Progesterone injection and method for preparing the same |
| US8241672B2 (en) | 2009-03-11 | 2012-08-14 | Stable Solutions Llc | Omega-3 enriched fish oil-in-water parenteral nutrition emulsions |
| RU2009145010A (en) | 2009-12-04 | 2011-06-20 | Общество с ограниченной ответственностью (ООО) "Аббифарм" (RU) | COMPOSITION OMEGA-3 AND OMEGA-6 POLYUNSATURATED FATTY ACIDS |
| TW201138782A (en) | 2010-04-26 | 2011-11-16 | Besins Healthcare Lu Sarl | Low-oil pharmaceutical emulsion compositions comprising progestogen |
| US8895074B2 (en) * | 2011-06-15 | 2014-11-25 | Stable Solutions Llc | Therapeutic application of parenteral krill oil |
| CN102277237B (en) * | 2011-06-20 | 2013-04-24 | 山东禹王制药有限公司 | Preparation method of high-purity glyceride type fish oil |
-
2013
- 2013-02-25 WO PCT/EP2013/053679 patent/WO2013127727A1/en active Application Filing
- 2013-02-25 JP JP2014559164A patent/JP2015508791A/en active Pending
- 2013-02-25 EP EP13706965.4A patent/EP2819650A1/en not_active Withdrawn
- 2013-02-25 CA CA2865030A patent/CA2865030C/en active Active
- 2013-02-25 BR BR112014021390A patent/BR112014021390A2/en not_active IP Right Cessation
- 2013-02-25 CN CN201380011584.6A patent/CN104136008A/en active Pending
- 2013-02-25 CN CN201380010731.8A patent/CN104136007A/en active Pending
- 2013-02-25 BR BR112014021391-7A patent/BR112014021391B1/en not_active IP Right Cessation
- 2013-02-25 CN CN201910525844.0A patent/CN110251463A/en active Pending
- 2013-02-25 MX MX2014010445A patent/MX2014010445A/en unknown
- 2013-02-25 PL PL13705798T patent/PL2819649T3/en unknown
- 2013-02-25 IN IN8089DEN2014 patent/IN2014DN08089A/en unknown
- 2013-02-25 RU RU2014139008A patent/RU2014139008A/en unknown
- 2013-02-25 WO PCT/EP2013/053686 patent/WO2013127728A1/en active Application Filing
- 2013-02-25 MX MX2014010442A patent/MX356427B/en active IP Right Grant
- 2013-02-25 ES ES13705798.0T patent/ES2659466T3/en active Active
- 2013-02-25 US US14/379,500 patent/US20150018320A1/en not_active Abandoned
- 2013-02-25 EP EP13705798.0A patent/EP2819649B1/en active Active
- 2013-02-25 RU RU2014138996A patent/RU2678319C2/en active
- 2013-02-25 PT PT137057980T patent/PT2819649T/en unknown
- 2013-02-25 US US14/379,505 patent/US9789122B2/en active Active
- 2013-02-25 JP JP2014559165A patent/JP6169110B2/en not_active Expired - Fee Related
- 2013-02-25 CA CA2864945A patent/CA2864945A1/en not_active Abandoned
- 2013-02-25 IN IN8088DEN2014 patent/IN2014DN08088A/en unknown
- 2013-02-25 NO NO13705798A patent/NO2819649T3/no unknown
- 2013-02-25 KR KR1020147024150A patent/KR102027613B1/en not_active Expired - Fee Related
- 2013-02-25 KR KR1020147024144A patent/KR20140131936A/en not_active Withdrawn
-
2014
- 2014-07-23 IL IL233760A patent/IL233760A0/en unknown
- 2014-07-23 IL IL233759A patent/IL233759B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN08088A (en) | ||
| MY165048A (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| EA201890852A1 (en) | VALBENASIN SALTS AND THEIR POLYMORPHES | |
| MX2014015004A (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof. | |
| MY188027A (en) | Fat composition and fat blend | |
| NZ716341A (en) | Glyceride composition | |
| MX363993B (en) | Pharmaceutical compositions with hydrating and lubricating activity. | |
| GT201400161A (en) | PHENYLIMIDAZOPIRAZOLES REPLACED AND ITS USE | |
| IL246254A0 (en) | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system | |
| FI3177281T3 (en) | Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies | |
| BR112014031306A2 (en) | pharmaceutical composition and its uses | |
| EP4385563A3 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| MX2016005900A (en) | Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment. | |
| MX2015015483A (en) | Hair treatment composition. | |
| BR112015001694A2 (en) | use of a composition for the manufacture of a medicament for treating skin disorders and / or abnormal cell proliferation disorders; composition; and method for preparing a pharmaceutical composition | |
| PH12014501051A1 (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| IL239512B (en) | Analogs and derivatives of alkyl fatty acids, pharmaceutical formulation comprising the same and use thereof | |
| EA201492238A1 (en) | COMPOSITION MIZOPROSTOL | |
| MX2016013680A (en) | Methods and compositions for treatment of lipid storage disorders. | |
| EA201692398A1 (en) | HOMOGENE COMPOSITION FOR ORAL ADMINISTRATION, CONTAINING OMEGA-3 POLYINSATURATED FATTY ACIDS AND RESVERATROL | |
| UA108535U (en) | ALIMENTARY METHOD OF PREVENTION AND TREATMENT OF DYSBIOTIC DISEASES | |
| MX358650B (en) | Solid ambroxol-containing preparation. | |
| WO2014031034A8 (en) | Pharmaceutical compositions containing ipidacrine and use thereof to treat potency disorders and other sexual activity disorders | |
| NZ621474A (en) | Levomilnacipran drug for functional rehabilitation after an acute neurological stroke | |
| UA94869C2 (en) | Use of lipoflavon as agent for treatment of acute cerebral trauma |